Phase 3 N=62 PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
Healthy
Primary: Prostate Tissue DHT Concentrations After Treatment — 4.05; 4.26; 2.99; 3.88 ng/g
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=468 A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 26 - Excluding Rescue Approach — -0.29; -0.41; -0.26 Percentage — p=0.807
Phase 3 N=152 Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Hypertension
Primary: Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint — -10.6; -8.83; -0.5; -2.11 mmHg — p== 0.001
Phase 3 N=91 A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose) — 1.71; 2.34; 1.88; 2.50 units on a scale
Phase 3 N=272 Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Diabetes Mellitus, Type 1
Primary: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12 — -0.21; -0.21 nanomoles per…
Phase 3 N=77 Drug Treatment for Pathologic Gambling Disorder
Gambling
Primary: Yale-Brown Obsessive Compulsive Scale for Pathological Gambling (PG-YBOCS) — 16.9; 18.6; 9.7; 12.9 units on a scale
Phase 3 N=309 Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
High Risk Acute Myeloid Leukemia
Primary: Overall Survival — 9.56; 5.95 months
Phase 3 N=466 Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.64; -0.06 Percentage change — p=<0.001
Phase 3 N=185 Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
Primary: The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown. — 88.3; 1.4 Adjusted percentage of responders — p=<0.0001
Phase 3 N=694 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Chronic Hepatitis C · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.0; 100.0; 100.0; 93.3 percentage of participants
Phase 3 N=231 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Carcinoid Tumor of the Small Bowel · Neuroendocrine Tumour
Primary: Progression Free Survival (PFS) — NA; 8.5 months — p=<0.0001
Phase 3 N=461 A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Type 2 Diabetes Mellitus
Primary: Change From Baseline In A1C at Week 26 — -0.79; -0.96; 0.20 Percent — p=<0.001
Phase 3 N=295 Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial
Cardiac Arrest
Primary: Survival With Good Neurobehavioral Outcome — 27; 15; 111; 107 Participants — p=0.14
Phase 3 N=201 Evaluation of N1539 Following Bunionectomy Surgery
Pain, Post-operative
Primary: Summed Pain Intensity Difference Over the First 48 Hours (SPID48) — -6956.0; -4829.3 units on a scale — p=0.0034
Phase 3 N=60 High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status
Hypovitaminosis D
Primary: Percent (%) Change in 25(OH)D 5 Days Following Supplementation With 100,000 IU Cholecalciferol — 8; -2 percent change in 25(OH)D